AMMOS Software: Method and Application

  • T. Pencheva
  • D. Lagorce
  • I. Pajeva
  • B. O. Villoutreix
  • M. A. Miteva
Part of the Methods in Molecular Biology book series (MIMB, volume 819)


Recent advances in computational sciences enabled extensive use of in silico methods in projects at the interface between chemistry and biology. Among them virtual ligand screening, a modern set of approaches, facilitates hit identification and lead optimization in drug discovery programs. Most of these approaches require the preparation of the libraries containing small organic molecules to be screened or a refinement of the virtual screening results. Here we present an overview of the open source AMMOS software, which is a platform performing an automatic procedure that allows for a structural generation and optimization of drug-like molecules in compound collections, as well as a structural refinement of protein-ligand complexes to assist in silico screening exercises.

Key words

3D structure generation Structure refinement Virtual screening AMMOS AMMP Open source/free software 



We thank the financial supports from the INSERM and University Paris Diderot. TP, MM and IP acknowledge the support of the Bulgarian National Science Fund (grants No. DTK02/58 and No. DO02/52).


  1. 1.
    Shoichet BK (2004) Virtual screening of chemical libraries. Nature 432:862–86.PubMedCrossRefGoogle Scholar
  2. 2.
    Villoutreix BO, Bastard K, et al (2008) In silico-in vitro screening of protein-protein interactions: towards the next generation of therapeutics. Curr Pharm Biotechnol 9:103–12.PubMedCrossRefGoogle Scholar
  3. 3.
    Clark D (2008) What has virtual screening ever done for drug discovery? Expert Opin Drug Discov 3:841–85.CrossRefGoogle Scholar
  4. 4.
    Vistoli G, Pedretti A and Testa B (2008) Assessing drug-likeness--what are we missing? Drug Discov Today 13:285–29.PubMedCrossRefGoogle Scholar
  5. 5.
    Lagorce D, Sperandio O, et al (2008) FAF-Drugs2: free ADME/tox filtering tool to assist drug discovery and chemical biology projects. BMC Bioinformatics 9:396PubMedCrossRefGoogle Scholar
  6. 6.
    Downs GM and Willett P (1995) Similarity searching in databases of chemical structures, In Reviews in Computational Chemistry (Lipkowitz KB, and Boyd DB, Eds.), pp 67–117, VCH Publishers NYGoogle Scholar
  7. 7.
    [] ROCS software
  8. 8.
    Sperandio O, Andrieu O, et al (2007) MED-SuMoLig: A New Ligand-Based Screening Tool for Efficient Scaffold Hopping. J Chem Inf Model 47:1097–111.PubMedCrossRefGoogle Scholar
  9. 9.
    Schwab CH (2010) Conformations and 3D pharmacophore searching. Drug Discovery Today: Technologies 7:e245–53.Google Scholar
  10. 10.
    Kuntz ID (1992) Structure-based strategies for drug design and discovery. Science 257:1078–108.PubMedCrossRefGoogle Scholar
  11. 11.
    Leach AR, Shoichet BK and Peishoff CE (2006) Prediction of protein-ligand interactions. Docking and scoring: successes and gaps. J Med Chem 49:5851–585.PubMedCrossRefGoogle Scholar
  12. 12.
    Bottegoni G, Kufareva I, et al (2009) Four-dimensional docking: a fast and accurate account of discrete receptor flexibility in ligand docking. J Med Chem 52:397–40.PubMedCrossRefGoogle Scholar
  13. 13.
    Sperandio O, Villoutreix BO and Miteva MA (2010) Structure-Based Virtual Screening, In In silico lead discovery (Miteva MA, Ed.), Bentham Science PublishersGoogle Scholar
  14. 14.
    Pencheva T, Soumana OS, et al (2010) Post-docking virtual screening of diverse binding pockets: comparative study using DOCK, AMMOS, X-Score and FRED scoring functions. Eur J Med Chem 45:2622–262.PubMedCrossRefGoogle Scholar
  15. 15.
    Bologa CG, Olah MM and Oprea TI (2006) Chemical database preparation for compound acquisition or virtual screening. Methods Mol Biol 316:375–38.PubMedGoogle Scholar
  16. 16.
    Lagorce D, Sperandio O, et al (2010) Chemical libraries for virtual screening, In In silico lead discovery (Miteva MA, Ed.), Bentham Science PublishersGoogle Scholar
  17. 17.
    Huang N, Kalyanaraman C, et al (2006) Molecular mechanics methods for predicting protein-ligand binding. Phys Chem Chem Phys 8:5166–517.PubMedCrossRefGoogle Scholar
  18. 18.
    Pencheva T, Lagorce D, et al (2008) AMMOS: Automated Molecular Mechanics Optimization tool for in silico Screening. BMC Bioinformatics 9:438PubMedCrossRefGoogle Scholar
  19. 19.
    Lagorce D, Pencheva T, et al (2009) DG-AMMOS: A New tool to generate 3D conformation of small molecules using Distance Geometry and Automated Molecular Mechanics Optimization for in silico Screening. BMC Chem Biol 9:6PubMedCrossRefGoogle Scholar
  20. 20.
    Weber IT and Harrison RW (1997) Molecular mechanics calculations on Rous sarcoma virus protease with peptide substrates. Protein Sci 6:2365–237.PubMedCrossRefGoogle Scholar
  21. 21.
    Crippen GM and Havel TF (1988) Distance geometry and molecular conformations, Wiley, New YorkGoogle Scholar
  22. 22.
    Rappé AK, Casewit CJ, et al (1992) UFF, a full periodic table force field for molecular mechanics and molecular dynamics simulations. J Am Chem Soc 114: 10024–1003.CrossRefGoogle Scholar
  23. 23.
    Bagossi P, Zahuczky G, et al (1999) Improved parameters for generating partial charges: correlation with observed dipole moments. J Mol Model 5:143–15.CrossRefGoogle Scholar
  24. 24.
    Berman HM, Westbrook J, et al (2000) The Protein Data Bank. Nucleic Acids Res 28:235–24.PubMedCrossRefGoogle Scholar
  25. 25.
    Sauton N, Lagorce D, et al (2008) MS-DOCK: Accurate multiple conformation generator and rigid docking protocol for multi-step virtual ligand screening. BMC Bioinformatics 9:184PubMedCrossRefGoogle Scholar
  26. 26.
    Moustakas DT, Lang PT, et al (2006) Development and validation of a modular, extensible docking program: DOCK 5. J Comput Aided Mol Des 20:601–61.PubMedCrossRefGoogle Scholar
  27. 27.
    Lagorce D, Villoutreix BO and Miteva MA (2011) Three-dimensional structure generators of drug-like compounds: DG-AMMOS, an open-source package. Expert Opinion on Drug Discovery 6:339–51Google Scholar
  28. 28.
    Miteva MA, Guyon F and Tuffery P (2010) Frog2: Efficient 3D conformation ensemble generator for small compounds. Nucleic Acids Res 38 Suppl:W622–62.PubMedCrossRefGoogle Scholar
  29. 29.
    Leite TB, Gomes D, et al (2007) Frog: a FRee Online druG 3D conformation generator. Nucleic Acids Res 35:W568–57.PubMedCrossRefGoogle Scholar
  30. 30.
    Vainio MJ and Johnson MS (2007) Generating conformer ensembles using a multiobjective genetic algorithm. J Chem Inf Model 47:2462–247.PubMedCrossRefGoogle Scholar
  31. 31.
    Watts KS, Dalal P, et al (2010) ConfGen: a conformational search method for efficient generation of bioactive conformers. J Chem Inf Model 50:534–54.PubMedCrossRefGoogle Scholar
  32. 32.
    Sperandio O, Souaille M, et al (2009) MED-3DMC: a new tool to generate 3D conformation ensembles of small molecules with a Monte Carlo sampling of the conformational space. Eur J Med Chem 44: 1405–140.PubMedCrossRefGoogle Scholar
  33. 33.
    Verma J, Khedkar VM and Coutinho EC (2010) 3D-QSAR in drug design--a review. Curr Top Med Chem 10:95–11.PubMedCrossRefGoogle Scholar
  34. 34.
    Renner S and Schneider G (2006) Scaffold-hopping potential of ligand-based similarity concepts. ChemMedChem 1:181–18.PubMedCrossRefGoogle Scholar
  35. 35.
    Osterberg F, Morris GM, et al (2002) Automated docking to multiple target structures: incorporation of protein mobility and structural water heterogeneity in AutoDock. Proteins 46:34–4.PubMedCrossRefGoogle Scholar
  36. 36.
    Trott O and Olson AJ (2010) AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J Comput Chem 31:455–46.PubMedGoogle Scholar
  37. 37.
    Verdonk ML, Chessari G, et al (2005) Modeling water molecules in protein-ligand docking using GOLD. J Med Chem 48: 6504–651.PubMedCrossRefGoogle Scholar
  38. 38.
    Venkatachalam CM, Jiang X, et al (2003) LigandFit: a novel method for the shape-directed rapid docking of ligands to protein active sites. J Mol Graph Model 21:289–30.PubMedCrossRefGoogle Scholar
  39. 39.
    Montes M, Miteva MA and Villoutreix BO (2007) Structure-based virtual ligand screening with LigandFit: pose prediction and enrichment of compound collections. Proteins 68:712–72.PubMedCrossRefGoogle Scholar
  40. 40.
    Cavasotto CN and Abagyan RA (2004) Protein flexibility in ligand docking and virtual screening to protein kinases. J Mol Biol 337:209–22.PubMedCrossRefGoogle Scholar
  41. 41.
    Amaro RE, Minh DD, et al (2007) Remarkable loop flexibility in avian influenza N1 and its implications for antiviral drug design. J Am Chem Soc 129:7764–776.PubMedCrossRefGoogle Scholar
  42. 42.
    Miteva MA, Robert CH, et al (2010) Receptor flexibility in ligand docking and virtual screening, In In silico lead discovery (Miteva MA, Ed.), Bentham Science PublishersGoogle Scholar
  43. 43.
    Cavasotto CN, Kovacs JA and Abagyan RA (2005) Representing receptor flexibility in ligand docking through relevant normal modes. J Am Chem Soc 127:9632–964.PubMedCrossRefGoogle Scholar
  44. 44.
    Sperandio O, Mouawad L, et al (2010) How to choose relevant multiple receptor conformations for virtual screening: a test case of Cdk2 and normal mode analysis. Eur Biophys J 39:1365–137.PubMedCrossRefGoogle Scholar
  45. 45.
    Segers K, Sperandio O, et al (2007) Design of protein-membrane interaction inhibitors by virtual ligand screening, proof of concept with the C2 domain of factor V. Proc Natl Acad Sci USA 104:12697–1270.PubMedCrossRefGoogle Scholar
  46. 46.
    Montes M, Braud E, et al (2008) Receptor-based virtual ligand screening for the identification of novel CDC25 phosphatase inhibitors. J Chem Inf Model 48:157–16.PubMedCrossRefGoogle Scholar
  47. 47.
    Wells JA and McClendon CL (2007) Reaching for high-hanging fruit in drug discovery at protein-protein interfaces. Nature 450:1001–100.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2012

Authors and Affiliations

  • T. Pencheva
    • 1
  • D. Lagorce
    • 2
  • I. Pajeva
    • 1
  • B. O. Villoutreix
    • 2
  • M. A. Miteva
    • 2
  1. 1.Institute of Biophysics and Biomedical EngineeringBulgarian Academy of SciencesSofiaBulgaria
  2. 2.Molécules Thérapeutiques in SilicoUniversité Paris DiderotParisFrance

Personalised recommendations